Caribou Biosciences (CRBU) Peer Comparison

$1.57

$0.00 (0.00%)

As on 04-Sep-2026 13:38EDT

Market cap

$174 Mln

Revenue (TTM)

$10 Mln

P/E Ratio

--

P/B Ratio

1.8

Div. Yield

0 %

Edit

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	174	16,765	16,261	13,492	12,332
Revenue ($ Mln)	10	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-103.40	491.50	755.85	860.62	-325.10
Net Margin (%)	-1,030.42	17.67	71.69	35.33	-25.32
RoE (%)	-93.88	110.09	--	42.98	-57.72
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	1.81	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	10.04	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	23.73	1,982.07	103.47	85.67	109.42
Gross Profit	7.51	760.62	588.53	2,236.43	902.26
Operating Expenses	96.46	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-109.47	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-103.95	598.92	101.11	1,035.47	-325.10
Provision for Tax	-0.55	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-103.40	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	98.10	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	26.70	187.89	384.48	288.55	346.72
Current Liabilities	17.97	1,435.43	464.70	361.93	374.20
Total Liabilities	175.37	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	26.18	1,006.90	895.24	1,243.41	45.47
Current Assets	116.60	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	175.37	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	26.66	120.10	449.89	165.93	347.75
Net Current Assets	0.00	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-110.99	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	102.24	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	4.82	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-69.08	53.56	-30.01	32.82	-31.49
ROE (%)	-93.88	110.09	163.18	42.98	-57.72
ROA (%)	-40.62	15.64	26.53	29.32	-22.97
EBIT Margin (%)	-793.93	21.13	5.73	31.04	-18.97
Net Margin (%)	-1,030.42	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	10.02	24.67	114.85	9.23	149.04
EBIT Growth (%)	46.31	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	37.05	17.50	378.76	42.89	-15.32
EPS Growth (%)	39.78	26.84	353.27	50.42	-0.64
Book Value Growth (%)	-45.60	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-1.01	36.06	-59.76	15.79	-45.32
Price / Book Value	1.23	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.26	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.00	0.00	0.65
Short term debt to equity ratio	0.01	0.00	0.05	0.00	0.00
Current Ratio	6.49	0.73	2.99	3.46	3.20
Quick Ratio	6.49	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-19.80

Operating Efficiency Ratios

	Caribou Biosciences (CRBU)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	19.34	15.88	21.25	13.74	14.98
Asset Turnover	0.04	0.89	0.37	0.83	0.91
Receivable days	101.96	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	413.80	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly